Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance - Summary - MDSpire
Advertisement
Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance
To evaluate the association between circulating sFlt-1 levels and peripartum cardiomyopathy (PPCM) and assess the overall diagnostic performance of sFlt-1, as well as its performance specifically in women with and without pre-eclampsia.
Key Findings:
Three studies (n = 226) met the criteria. High sFlt-1 levels were associated with increased PPCM risk (pooled OR 1.79; 95% CI 1.22–2.64).
In women with pre-eclampsia, the association with PPCM was stronger (OR 2.11; 95% CI 1.45–3.09) compared to those without (OR 1.36; 95% CI 1.03–1.80).
Diagnostic performance was modest: sensitivity 72% (95% CI 64%–80%), specificity 57% (95% CI 44%–68%), AUC 0.71 (95% CI 0.67–0.75).
Interpretation:
Elevated sFlt-1 is associated with PPCM, with improved diagnostic performance observed in women with pre-eclampsia, indicating potential for better risk stratification.
Limitations:
All included studies measured sFlt-1 in the postpartum period, limiting antepartum screening utility.
Substantial heterogeneity was present across studies, which may affect the reliability of the pooled estimates.
Conclusion:
Larger prospective studies with measurements during pregnancy and serial peripartum follow-up are needed to validate these findings and assess clinical applicability.
